What’s Enanta Pharmaceuticals Inc (ENTA) Upside After Today’s Significant Increase?

September 17, 2017 - By Vivian Currie

Investors sentiment decreased to 1.47 in 2016 Q4. Its down 0.06, from 1.53 in 2016Q3. It worsened, as 13 investors sold Enanta Pharmaceuticals Inc shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported.
Morgan Stanley has invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). 22,300 are held by Swiss Bankshares. Ameriprise Fincl stated it has 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Great Point Partners Lc reported 828,253 shares. Gsa Capital Prns Ltd Liability Partnership holds 0.15% or 77,309 shares in its portfolio. Assetmark Inc reported 0% stake. 30,990 were accumulated by D E Shaw Incorporated. Pacad Inv reported 1,800 shares stake. Weiss Multi stated it has 0.03% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Matarin Capital Mgmt Limited Company has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 257,268 shares. Ls Invest Advsrs Ltd Co owns 483 shares for 0% of their portfolio. Blackrock Invest Mngmt Limited Com holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 85,043 shares. Pnc Financial Svcs Group reported 84,236 shares stake. Eqis Cap Mgmt holds 0.07% or 35,326 shares in its portfolio. Shell Asset Mngmt Communication owns 15,946 shares for 0.01% of their portfolio.

The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! The stock increased 4.55% or $1.96 on September 15, reaching $45.06. About 355,589 shares traded or 88.35% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since September 17, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.
The move comes after 8 months positive chart setup for the $860.21 million company. It was reported on Sep, 17 by Barchart.com. We have $48.66 PT which if reached, will make NASDAQ:ENTA worth $68.82 million more.

Wall Street await Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to release earnings on November, 20. Analysts forecast EPS of $1.94, up exactly $2.03 or 2,255.56 % from 2014’s $-0.09 EPS. The expected ENTA’s profit could reach $37.04M giving the stock 5.81 P/E in the case that $1.94 earnings per share is reported. After posting $-0.44 EPS for the previous quarter, Enanta Pharmaceuticals Inc’s analysts now forecast -540.91 % EPS growth.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Enanta Pharmaceuticals Inc had 14 analyst reports since August 7, 2015 according to SRatingsIntel. JMP Securities upgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) rating on Friday, October 23. JMP Securities has “Mkt Outperform” rating and $32 target. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Overweight” rating given on Tuesday, August 9 by JP Morgan. The rating was upgraded by JMP Securities to “Market Outperform” on Tuesday, July 11. On Thursday, April 28 the stock rating was downgraded by JMP Securities to “Market Perform”. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Underweight” rating given on Friday, October 23 by Barclays Capital. The company was downgraded on Saturday, August 8 by TheStreet. Zacks downgraded the stock to “Buy” rating in Friday, August 7 report. Robert W. Baird maintained it with “Neutral” rating and $36 target in Tuesday, August 8 report.

More notable recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Businesswire.com which released: “Enanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its …” on September 13, 2017, also Seekingalpha.com with their article: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Q2 2017 Results – Earnings Call …” published on May 08, 2017, Seekingalpha.com published: “Enanta: Half Cash, All Upside” on February 28, 2017. More interesting news about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Biotech Forum Daily Digest: Fallout From The ACA Repeal Debacle. Spotlight On …” published on March 27, 2017 as well as Seekingalpha.com‘s news article titled: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Fiscal Q3 2017 Results …” with publication date: August 08, 2017.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $860.21 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.